 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4749 News |  |
| 12345678910111213...6061» |
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: Obinutuzumab for the Treatment of Cold Agglutinin Disease: A Case Report. (Pubmed Central) - Jun 14, 2024
No abstract available
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Biomarker, Journal, IO biomarker: Prognostication in chronic lymphocytic leukemia. (Pubmed Central) - Jun 8, 2024
In the context of the aggressive transformation of CLL, namely Richter syndrome, the clonal relationship to the CLL counterpart represents the strongest prognostic biomarker. Clonally related Richter syndrome still represents an unmet clinical need which requires further efforts to identify new therapeutic strategies.
- || Review, Journal: Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia. (Pubmed Central) - Jun 7, 2024
Promising novel approaches include BTK degraders, bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T)-cell therapy. What is clear is that CIT is archaic, and current and future targeted approaches will continue to improve the outcome for patients with chronic lymphocytic leukemia.
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: Development of psoriasis during obinutuzumab treatment in a patient with follicular lymphoma. (Pubmed Central) - Jun 7, 2024
What is clear is that CIT is archaic, and current and future targeted approaches will continue to improve the outcome for patients with chronic lymphocytic leukemia. No abstract available
- | Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
Journal: An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL. (Pubmed Central) - Jun 3, 2024
P3
No other significant differences in safety were observed. In summary, compared with zanubrutinib, acalabrutinib plus obinutuzumab had longer INV-PFS with increased odds of neutropenia and arthralgia, whereas acalabrutinib monotherapy had similar INV-PFS with lower odds of any grade hypertension.
- Columvi (glofitamab-gxbm) / Roche
GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO) (Hall Picasso) - Jun 3, 2024 - Abstract #EHA2024EHA_4360;
P3
Glofitamab is the first CD20:CD3 bispecific antibody todemonstrate survival benefit in DLBCL in a randomized Phase III trial. Glofit-GemOx, a fixed-duration, off-the-shelf regimen, was well tolerated with a safety profile consistent with known risks of each individual agent.
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: A Case of Primary Adrenal Insufficiency Triggered by Cytomegalovirus Infection after Obinutuzumab plus Bendamustine Therapy for Follicular Lymphoma. (Pubmed Central) - May 30, 2024
PAI caused by CMV infection has mainly been reported in patients with acquired immunodeficiency syndrome. In the present case, the PAI triggered by CMV infection led to immunodeficiency after chemotherapy.
- OFF-LABEL USE OF BIOLOGICS AND SMALL MOLECULES IN SJ () - May 29, 2024 - Abstract #EULAR2024EULAR_3111;
Nearly 85% of therapies are directed against B cells (overwhelmingly rituximab), with exceptional cases of new anti-CD20 monoclonal antibodies or combined therapy with rituximab and belimumab. Mortality is higher than expected in SjD treated with the biologic and small molecule therapies [1], infections (notably COVID-19 in patients treated with rituximab) and cancer progression being the most frequent causes of death, thus highlighting the need for defining advanced treatment indications in SjD.
- || Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
PK/PD data, Journal: Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) - May 29, 2024
The 60?mg loading doses increased Mosun CD20 RO% in Cycle 1, providing efficacious exposures in the presence of the competing anti-CD20 drugs. PopPK model simulations, investigating Mosun dose delays, informed treatment resumption protocols to ensure CRS mitigation.
- || Review, Journal, IO biomarker: Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia. (Pubmed Central) - May 28, 2024
Covalent BTKi-refractory patients should be treated with venetoclax plus rituximab, whereas venetoclax-refractory CLL may be treated with second generation BTKi in the case of early relapse, while venetoclax plus rituximab might be used if late relapse has occurred. On these grounds, here we provide an overview of the current state-of-the-art therapeutic algorithms for treatment-na
- || Gazyva (obinutuzumab) / Roche, Biogen
Review, Journal: Progressive multifocal leukoencephalopathy following obinutuzumab and bendamustine therapy for follicular lymphoma: case report and literature review. (Pubmed Central) - May 27, 2024
On these grounds, here we provide an overview of the current state-of-the-art therapeutic algorithms for treatment-na No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen
Retrospective data, Journal: Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis. (Pubmed Central) - May 27, 2024
In this small cohort of treatment-refractory patients with DLBCL, the combination of radiation and obinutuzumab was well tolerated without excessive treatment-related toxicity. The combination resulted in durable disease control with a prolonged overall survival without additional treatment in a subset of patients.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Review, Journal: A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment. (Pubmed Central) - May 24, 2024
This review assesses the efficacy of anti-CD20 therapies, including rituximab, ofatumumab, ocrelizumab, and obinutuzumab, in pemphigus treatment...The dynamic landscape of emerging therapies and personalized medicine emphasizes the need for ongoing research and strategic clinical decision-making. This review is a foundation for future investigations, providing insights for clinicians and researchers in optimizing pemphigus treatment.
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial completion date, Trial termination: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (clinicaltrials.gov) - May 15, 2024
P2, N=32, Terminated, Sponsor: OHSU Knight Cancer Institute
This review is a foundation for future investigations, providing insights for clinicians and researchers in optimizing pemphigus treatment. N=60 --> 32 | Trial completion date: Jan 2025 --> Mar 2024 | Recruiting --> Terminated; Study transferred to new coordinating center: Providence Health & Services
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
P1 data, Journal: A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report. (Pubmed Central) - May 9, 2024
N=60 --> 32 | Trial completion date: Jan 2025 --> Mar 2024 | Recruiting --> Terminated; Study transferred to new coordinating center: Providence Health & Services Not available.
- || Columvi (glofitamab-gxbm) / Roche, Yescarta (axicabtagene ciloleucel) / Gilead
Enrollment open: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (clinicaltrials.gov) - May 8, 2024
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not available. Not yet recruiting --> Recruiting
- | Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. (Pubmed Central) - May 7, 2024
P1/2
Extensive sensitivity analyses assessed the importance of these uncertainties. Mosunetuzumab is estimated to be cost-effective compared with approved regimens except R-Len for the treatment of adults with R/R FL.
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Variable Presentation of Post-Transplant Lymphoproliferative Disease after Kidney Transplant - A Single Center Experience (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_268;
Although there is a strong association between EBV and PTLD, many cases were not associated with EBV. Treatment depends on morphologic subtype.
- | Venclexta (venetoclax) / Roche, AbbVie, Polivy (polatuzumab vedotin-piiq) / Roche
Journal: Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) - May 3, 2024
CR rates at EOI were 59.2% (FL) and 31.3% (DLBCL); median progression-free survival was 22.8?months (95% confidence interval [CI], 14.5-not evaluable) and 4.6?months (95% CI, 3.6-8.1), respectively. Polatuzumab vedotin plus venetoclax and obinutuzumab/rituximab had acceptable safety in patients with R/R FL or DLBCL, with promising response rates in R/R FL, including high-risk patients.
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Journal: Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment. (Pubmed Central) - May 2, 2024
Polatuzumab vedotin plus venetoclax and obinutuzumab/rituximab had acceptable safety in patients with R/R FL or DLBCL, with promising response rates in R/R FL, including high-risk patients. No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Journal: Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients. (Pubmed Central) - Apr 26, 2024
P2, P3
Causes of death were comparable in the 2 groups, the most common cause being lymphoma. Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients.
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Journal: Pairing obinutuzumab with venetoclax in relapsed CLL. (Pubmed Central) - Apr 26, 2024
Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients. No abstract available
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Journal, HEOR, Real-world evidence, Real-world: Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. (Pubmed Central) - Apr 26, 2024
One (3%) patient experienced laboratory TLS with obinutuzumab initiation. In summary, this retrospective cohort study demonstrated that Ven-O achieves frequent, durable responses and can be safely administered in r/r CLL/SLL.
- || Review, Journal: Advancements in the Management of Follicular Lymphoma: A Comprehensive Review. (Pubmed Central) - Apr 25, 2024
Given encouraging outcomes with CAR T cell therapy and BsAbs, multiple trials are testing these highly active agents in earlier lines of therapy and among high-risk patients with early relapse after frontline chemoimmunotherapy. Additonal studies and follow-up are needed to understand how these novel agents may further change treatment algorithms for FL.
- Rituxan (rituximab) / Roche
Real world outcomes in patients with follicular lymphoma treated with RCHOP vs BR. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5025;
Among patients w G 3A FL, there was no significant improvement in TTNT with RCHOP. Rituximab mtn was associated w improved OS.
- Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4995;
These findings suggest the need for better treatment options for patients with FL, especially in 3L and 4L. >NA = Not applicable.
- Gazyva (obinutuzumab) / Roche, Biogen
Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4984;
The real-world data comparison of 1L treatment in high-risk pts with CLL/SLL shows that, after 30 months, the probability of not initiating the next treatment is 92% for those treated with a BCL2i compared to 76% for those treated with a BTKi. Additional follow-up and a larger sample may be needed to further validate these findings.
- Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4529;
PROs were discordant with qualitative interviews and suggested that FT may be driven by factors other than OOP costs. Although funding and patient assistance programs were beneficial, uncertainty over losing funding may be a long-term driver of FT and merits further study.
- CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na (Hall A; Poster Bd #: 68a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2422;
P3
Other secondary endpoints include PFS as assessed by investigator (INV); CRR by INV; rate of uMRD4 based on flow cytometry; overall response rate by IRC and INV; duration of response by IRC and INV; patient-reported outcomes; and safety and tolerability. Recruitment is ongoing.
- Rituxan (rituximab) / Roche, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R 2 ) vs chemoimmunotherapy or R 2 in previously untreated follicular lymphoma. (Hall A; Poster Bd #: 66b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2419;
P1/2, P3
Most patients with advanced-stage FL in need of systemic therapy are treated with an anti-CD20 monoclonal antibody (eg, rituximab [R] or obinutuzumab [G]) with cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or bendamustine [benda]). Safety endpoints include incidence and severity of adverse events (AEs), including AEs of special interest (cytokine release syndrome, immune effector cell
- Gazyva (obinutuzumab) / Roche, Biogen, Tecentriq (atezolizumab) / Roche
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. (Hall A; Poster Bd #: 53) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2405;
P1, P2
Our phase 2 study of 1L nivolumab + rituximab in FL yielded 92% overall response rate (ORR), (54% Complete Response (CR)). Atezolizumab +Obinutuzumab +/- PET-adapted 4Gy RT yielded high complete response rates with low toxicity in treatment-na
- Columvi (glofitamab-gxbm) / Roche
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study. (Hall A; Poster Bd #: 3) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2357;
P1/2
Atezolizumab +Obinutuzumab +/- PET-adapted 4Gy RT yielded high complete response rates with low toxicity in treatment-na Initial treatment included obinutuzumab pre-treatment (Gpt) 7 days before the first glofitamab dose, then glofitamab intravenously at either a fixed dose of 0.015
- Columvi (glofitamab-gxbm) / Roche
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2345;
P1/2, P3
Fixed-duration glofitamab continues to demonstrate compelling response rates that are maintained beyond EOT, with long-term durability observed in heavily pretreated pts with R/R MCL, including pts with prior BTKi therapy. The safety profile was manageable and CRS mainly low grade.
- Anyara (naptumomab estafenatox) / NeoTX
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) (Hall A; Poster Bd #: 479) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1489;
P2
These preliminary results of NAP + docetaxel show potential evidence of activity with acceptable safety in heavily pre-treated NSCLC pts. Further trials of NAP in combination, including CPIs are planned.
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Journal: Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG). (Pubmed Central) - Apr 23, 2024
Further trials of NAP in combination, including CPIs are planned. Moreover, CD20 antibody (Rituximab or Obinutuzumab)-based treatments within the last 6
- | Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
Journal, HEOR: Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. (Pubmed Central) - Apr 23, 2024
Moreover, CD20 antibody (Rituximab or Obinutuzumab)-based treatments within the last 6 Over 3 years, the estimated cumulative per patient cost of mosunetuzumab is lower than most available newer therapies, resulting in a small increase in the budget after its formulary adoption for the treatment of relapsed or refractory follicular lymphoma.
- ||| Jaypirca (pirtobrutinib) / Eli Lilly, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Trial initiation date: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 22, 2024
P2, N=60, Recruiting, Sponsor: Inhye Ahn
Over 3 years, the estimated cumulative per patient cost of mosunetuzumab is lower than most available newer therapies, resulting in a small increase in the budget after its formulary adoption for the treatment of relapsed or refractory follicular lymphoma. Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Apr 2024
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Journal: Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia. (Pubmed Central) - Apr 22, 2024
Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Apr 2024 No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: 17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Apr 22, 2024
P2, N=30, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
No abstract available Trial primary completion date: Feb 2024 --> Dec 2024
- Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Risk Factors in Breakthrough Reactions during Monoclonal Antibody Desensitization (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_1725;
Grade 3 HSR, and/or immediate mixed-reactions are risk factors for presenting a BTR. Although female sex did not reach a statistical significance as a risk factor for having BTR, a trend has been observed.
- | Calquence (acalabrutinib) / AstraZeneca
Retrospective data, Journal, IO biomarker: Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials. (Pubmed Central) - Apr 19, 2024
The safety profile of acalabrutinib-based therapy in this population was consistent with the known safety profile of acalabrutinib in a broad CLL population. Our analysis demonstrates long-term benefit of acalabrutinib-based regimens in patients with higher-risk CLL, regardless of line of therapy.
- || Columvi (glofitamab-gxbm) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: GLORIFY: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (clinicaltrials.gov) - Apr 18, 2024
P2, N=40, Recruiting, Sponsor: French Innovative Leukemia Organisation
Our analysis demonstrates long-term benefit of acalabrutinib-based regimens in patients with higher-risk CLL, regardless of line of therapy. Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date, Adverse events: ReVenG: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Apr 18, 2024
P2, N=75, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial completion date: Jan 2029 --> Jul 2027
- | Columvi (glofitamab-gxbm) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Calquence (acalabrutinib) / AstraZeneca
Enrollment open: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 17, 2024
P2, N=40, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2029 --> Jul 2027 Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Journal: Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma. (Pubmed Central) - Apr 17, 2024
Not yet recruiting --> Recruiting No abstract available
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Apr 17, 2024
P2, N=95, Recruiting, Sponsor: National Cancer Institute (NCI)
No abstract available Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
- ||||| Calquence (acalabrutinib) / AstraZeneca
Enrollment closed: MAJIC: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 16, 2024
P3, N=607, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025 Recruiting --> Active, not recruiting
- | Scemblix (asciminib) / Novartis
Journal: Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts. (Pubmed Central) - Apr 13, 2024
P1/2, P2
Other monoclonal antibodies, such as tafasitamab (anti-CD19), obinutuzumab (anti-CD20) and epratuzumab (anti-CD22) have been tested in trials (NCT05366218, NCT04920968, NCT00098839)...In contrast to ATP site inhibitors such as dasatinib and ponatinib, the novel first-in-class selective allosteric ABL myristoyl pocket (STAMP) inhibitor asciminib did not significantly impact ADCC in our settings. Our results suggest that asciminib should be considered in clinical trials.
- || Columvi (glofitamab-gxbm) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
New P1/2 trial: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 9, 2024
P1/2, N=27, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- Venclexta (venetoclax) / Roche, AbbVie
Real-world treatment patterns after discontinuation of venetoclax or BTKis among older US Medicare beneficiaries with chronic lymphocytic leukemia in the front-line setting () - Apr 9, 2024 - Abstract #AMCP2024AMCP_54;
In this real-world study of older pts with CLL in the United States, most pts treated with 1L VenO received fixed duration therapy and did not initiate subsequent CLL treatment. Conversely, 38% of pts on 1L BTKi discontinued their index treatment at a median of 3.6 months, and nearly 40% of these pts initiated another CLL treatment.